Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study.

Anne Sophie Koldkjær Sølling Diana Hedevang ChristensenB DarvalicsTorben Harsløf Reimar Wernich Thomsen Bente Lomholt Langdahl

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)

In a real-world setting, less than 50% continued ALN treatment for 5 years. We found no difference in the risk of fractures in patients discontinuing versus continuing ALN after 5 years.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes